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Pneumocystis jirovecii is a ubiquitous fungus causing pneumonia in humans. Diagnosis 17 
was hampered by the inability to culture the organism, with diagnosis based on 18 
microscopic examination of respiratory samples. Performance of microscopy was 19 
improved by immunofluorescent (IF) testing using monocloncal antibodies targeting 20 
both cyst and trophic forms. Although microscopy is specific, with positivity used to 21 
define disease, poor sensitivity meant negativity could not exclude it. 22 
New assays can assist in the diagnosis. PCR has permitted testing of respiratory samples 23 
other than bronchoalveolar lavage (BAL), easing sampling pressures. PCR has greater 24 
sensitivity than IF but questions remain as to the significance of low level positivity, in 25 
respect to colonisation versus disease associated with low fungal burdens. Conversely, 26 
PCR negativity in BAL samples can exclude disease, provided sampling is adequate. The 27 
presence of 1-3-β-D-Glucan in serum is also a useful biomarker, providing high 28 
sensitivity. However, 1-3-β-D-Glucan is not specific to Pneumocystis jirovecii pneumonia 29 
(PCP), and definitive thresholds for PCP are not available. Combination testing has the 30 
potential to both diagnose and exclude PCP. Recommendations on prophylactic and 31 




Pneumocystis jirovecii pneumonia (PCP) was an early indicator of the HIV epidemic and 34 
occurred in 70-80% of AIDS patients. 1-3 The incidence of PCP associated with HIV has 35 
fallen, a result of earlier HIV diagnoses, better anti-retroviral therapy and the use of 36 
prophylaxis. Most HIV associated cases of PCP now occur in patients with undiagnosed 37 
HIV. 4, 5 There is an increasing population of susceptible non-HIV patients, including 38 
those with solid malignancies, solid organ transplant and haematopoietic stem cell 39 
transplant recipients, patients  receiving immuno-suppressive therapies for auto-40 
immune and inflammatory conditions and those with genetic primary immune 41 
deficiency disorders.6  A national study over the decade 2000-2010 showed an annual 42 
average increase in incidence of 9%, and the largest cohort associated with PCP were 43 
those suffering from underlying haematological malignancy. 5 Cases of PCP have also 44 
been diagnosed in less typical scenarios, such as in non-HIV individuals suffering from 45 
Dengue fever and those with pre-existing lung disease. 5, 7 46 
Children are exposed to Pneumocystis at early age, between the ages of 2-4 years old 47 
over 80% of children will have generated antibodies. Reactivation of latent infection 48 
was a presumed source of infection in susceptible hosts later in life.8, 9 However, several 49 
documented PCP outbreaks confirm anthropophilic transmission, likely by airborne 50 
dispersal. Furthermore, typing revealed that infection was associated with place of 51 
diagnosis rather than place of birth. 10 Increased risk for developing PCP is associated 52 
with immuno-suppression, primarily a reduction in the CD4 lymphocyte count or 53 
lymphocyte dysfunction. A summary of risk factors is listed in Table 1. 54 
The primary manifestations are associated with the respiratory tract, with extra-55 
pulmonary disease, potentially associated with any organ, a rare manifestation. 56 
Symptoms are generally non-specific, including fever, non-productive cough, worsening 57 
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chest pain, shortness of breath (especially on exertion), with the severity of symptoms 58 
often greater in non-HIV patients. 11 In mild cases initial examination may appear 59 
normal, although under exertion heart rate and oxygenation levels may become 60 
abnormal. 11 In HIV+ patients the onset of symptoms can be indolent often delaying 61 
diagnosis by weeks, whereas in non-HIV patients PCP presentation is acute, often 62 
fulminant, particularly after corticosteroid administration.12 The mortality rate in HIV+ 63 
patients ranges from 17-30%, whereas in non-HIV patients are higher ranging from 28-64 
53%. 12 65 
Given the non-specific nature of the clinical findings further investigations specific to 66 
Pneumocystis are necessary to confirm a diagnosis of PCP even in symptomatic high-risk 67 
patients and diagnosis should not be based on clinical presentation and radiology. 13 68 
Microscopic examination and molecular testing of respiratory samples are available but 69 
both have different performance limitations. Alternatively, serum/plasma samples can 70 
be tested for the presence of (1-3)-β-D-Glucan (BDG), although this assay cannot 71 
differentiate between the broad range of fungal pathogens it is capable of detecting.  72 
Clinical investigations (e.g. radiology) can provide insight in likelihood of PCP by 73 
showing evidence of the disease process or potential host response to infection, but 74 
again lack aetiological specificity. Recent guidelines for the diagnosis and management 75 




Understanding test formats 78 
The incidence of a disease influences utility of diagnostic tests, and can determine the 79 
optimal testing strategy in different clinical settings. Before ordering any test, clinicians 80 
should decide how the test result (positive or negative) would affect the management of 81 
their patient. If both outcomes are the same then the test has no clinical value. Clinicians 82 
often focus on a purely diagnostic approach, but many tests are better suited to exclude 83 
a diagnosis, avoiding the need for unnecessary therapy. Testing can also be used 84 
prognostically to monitor disease and assess the duration and response to therapy. 85 
For most cohorts the incidence of PCP is relatively low and the pre-test probability of 86 
disease is small compared to the pre-test probability of not having disease. 87 
Consequently, negative results are better suited to excluding disease through a high 88 
sensitivity and negative predictive value (NPV). With high sensitivity comes potential 89 
false positivity but specificity can be improved by intensifying the diagnostic work-up 90 
through repeat and combination testing, and multi-disciplinary interpretation of results. 91 
Different sample types, for example upper and lower respiratory tract specimens and 92 
even blood samples, may shift the emphasis of the result from sensitivity/NPV to high 93 
specificity/positive predictive value (PPV).  94 
 95 
Radiological investigations 96 
Chest radiography (CXR) may be normal during the early stages of disease, but can 97 
worsen rapidly, particularly in the non-HIV population. 11, 12, 17 Computerised 98 
tomography (CT) scans are more sensitive than conventional radiographic techniques, 99 
providing evidence of infection even during the early stages of disease in non-HIV 100 
patients, and there is a role for CT despite CXR negativity. 18, 19 CXR typically presents 101 
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with bilateral, diffuse interstitial infiltrates that progress to bilateral consolidations. 11, 102 
18, 20  103 
CT generally demonstrates bilateral, symmetric patchy ground-glass attenuation. 104 
Consolidations may be present in mid or late stages of disease. 12, 18 Other findings 105 
include nodules, cysts, pneumothoraces, upper lobe localization, linear opacities and 106 
septal thickening. 11, 12, 20, 21 Cavitation, intra-thoracic adenopathy and pleural effusions 107 
are less likely. 11, 16, 21 The radiological presentation of PCP is not specific and can imitate 108 
other pathogens (e.g. bacterial pneumonia). 22 Radiology cannot provide an aetiological 109 
diagnosis, but may be used to initiate empirical therapy in high risk patients. This 110 
should trigger efforts to achieve a mycological diagnosis of the organism from the 111 
respiratory tract. 112 
Recent developments for the imaging of PCP include the successful application of ultra 113 
low dose chest CT, fluorodeoxyglucose positron emission tomography (FDG-PET) and 114 
bronchoscopic probe-based confocal laser endomicroscopy. 23-25 CT has also been used 115 
to determine the severity and prognosis of PCP infection.18, 21 116 
 117 
Non-Microbiological Laboratory Investigations 118 
Overall lymphocyte count should be determined, as values <10% of the norm has been 119 
associated with a poor prognosis in PCP infection. 26 Lymphocyte function in addition to 120 
absolute numbers may also be significant and the role of recent immunosuppressant 121 
drugs and other biological response modifying agents should be considered.  122 
Hypoxaemia will vary depending on the severity of disease and HIV status, and 123 
regularly presents as a mild and severe reduction arterial oxygen in HIV+ and non-HIV 124 
patients, respectively. 11, 12 Serum lactate dehydrogenase (LDH) elevation is a suggestive 125 
marker, with levels >500ml/dL associated with PCP. 11 Extracellular LDH indicates cell 126 
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damage or cell death, with elevated levels correlating with lung tissue damage, but it is 127 
not specific for PCP and is of little use outside the HIV+ population. In a study of LDH in 128 
performance in HIV+ and non-HIV cohorts the sensitivity and specificity were 129 
100%/47% and 63%/43%, respectively, showing that within HIV+ cohort a negative 130 
result could be used to confidently exclude disease, but positivity required confirmatory 131 
testing. 27 The use of procalcitonin serum concentration to differentiate PCP from other 132 
respiratory infections and/or colonisation is not clear. 28-30 133 
Clinical factors have also been used to predict mortality.  In large observational cohort 134 
study of 451 HIV+ patients five significant predictors (Age, recent intravenous drug use, 135 
total bilirubin, serum albumin and alveolar-aterial oxygen gradient) were determined 136 
through multivariate analysis and incorporated into model to predict PCP mortality. 31 137 
 138 
Conventional Techniques – Culture 139 
The difficulty in culturing Pneumocystis has hindered both diagnosis and research and 140 
development. Several methods using various co-culture cell lines were described but 141 
failed to attain widespread use. 32 Most attempts have used rat-models and 142 
subsequently P. carinii not P. jirovecii. In 1999, P. carinii initially isolated from rat lung 143 
was cultured using continuous axenic cultivation. 33 This complex technique has been 144 
successfully applied to the recovery of P. carinii from lungs and BAL fluid of rats and 145 
used to investigate life-cycle, but has limited use in routine diagnostics. 34-36  146 
In 2014, the first successful cultivation and propagation of P. jirovecii direct from BAL 147 
was achieved using a three-dimensional air-liquid interface culture system formed by 148 
CuFi-8 respiratory epithelial cell line. 32 While this represents a major breakthrough and 149 
provides the potential to perform antifungal susceptibility testing, it still requires cell 150 
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culture, limiting its use in routine diagnostics laboratories, being replaced by direct 151 
molecular methods. 152 
 153 
Conventional Techniques – Microscopy 154 
The gold standard for the diagnosis of PCP remains the histological and microscopic 155 
identification of ascus (cysts containing ascospores) and trophic forms using Wright’s-156 
Giemsa, toluidine blue O, calcofluor white or Grocott-Gomori stains, in tissue, BAL and 157 
induced sputum. While Gomori stains the cell wall of the ascus form, Giemsa will stain 158 
both ascus and trophic forms but do not stain the cell wall. Toluidine blue is a generic 159 
stain for nucleic acids and polysaccharides, while calcofluor white stains chitin and 160 
cellulose, neither is specific for Pneumocystis. The performance of conventional stains 161 
has been superseded by IF microscopy using anti-P. jirovecii monoclonal antibodies. 12 162 
However, in the majority of studies only the ascus form was targeted and a combination 163 
of stain and/or IF kit to detect both ascus and trophic forms is recommended. IF kits 164 
that detect both forms are available ȋe.g. Monofluo™ Pneumocystis jirovecii IFA or 165 
Merifluor Pneumocystis kits). 12  166 
In a comparison of four staining methods sensitivities were 73.8%, 76.9%, 48.4% and 167 
90.8%, for calcofluor white, Grocott-Gomori, Diff-Quik ȋmodified Wright’s-Giemsa) and 168 
Merifluor Pneumocystis respectively. 37 The sensitivity of the Diff-Quik method was 169 
significantly lower than the other methods. For conventional stains the corresponding 170 
specificity was >99%, whereas for the IF antibody assay (Merifluor Pneumocystis kit) it 171 
was 94.7%, significantly lower than the other methods. 37 The authors concluded that 172 
the Merifluor Pneumocystis kit was a useful screen to exclude PCP but the 173 
specificity/PPV was insufficient to confirm disease. However, the positive likelihood 174 
ratio (less affected by prevalence) for the Merifluor Pneumocystis kit was 17.1, and 175 
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subsequent positive results are associated with PCP. Conversely, none of the non-IF 176 methods generated a negative likelihood ratio ζͲ.ͳ, and cannot be used to exclude 177 
disease confidently.  178 
For microscopic approaches a primary screen with a highly sensitive IF method 179 
confirmed by a secondary specific method is recommended. 12 A summary of the 180 
comparative performance of various microscopic staining and fluorescent techniques 181 
for the diagnosis of PCP is shown in table 2. 38-40  182 
It is important to consider the influence of specimen type and quality on assay 183 
performance. There is no standardised approach to sampling the respiratory tract and 184 
protocols will vary across centres affecting the quality of BAL and sputa. When 185 
comparing both IF and conventional staining on sputum and BAL, the sensitivity was 186 
lower when testing sputum across all assays. 40 In a meta-analysis involving seven 187 
studies with 160 cases and 162 controls the sensitivity and specificity of staining and IF 188 
of induced sputum was determined using BAL testing as a reference. 41 Overall 189 
sensitivity and specificity when testing induced sputum was 55.5% and 98.6%, 190 
respectively, although the sensitivity when IF testing (67.1%) was significantly greater 191 
than conventional staining (43.1%). 41  192 
 193 
(1-3)-Β-D-Glucan 194 
The use of assays to detect (1-3)-β-D-Glucan (BDG) is now widely accepted and permits 195 
the testing of easily obtainable serum/plasma specimens. Clinical trials of BDG 196 
performance for the diagnosis of PCP are lacking but various meta-analyses of clinical 197 
evaluations exist (Table 3). 42-44 Overall, sensitivity is high and BDG negativity can be 198 
used to exclude PCP, although false negatives have been noted.45 Specificity is 199 
suboptimal (<90%).42-44  A BDG positive result alone cannot be considered diagnostic of 200 
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PCP, due to the assays broad detection range coupled with a patient cohort that may 201 
susceptible to other fungal pathogens. The result should be interpreted along with 202 
radiological findings together with a PCP specific assay. Specificity will also be affected 203 
by non-infective factors such as potential sources of false positivity.46 For the diagnosis 204 
of PCP there was no difference in the overall accuracy of BDG assays developed by 205 
different manufacturers. 43 In one meta-analysis, BDG performance when testing 206 
samples from HIV+ versus HIV- patients was comparable, although in a more recent 207 
study sensitivity was deemed to be significantly lower in the non-HIV population (HIV+: 208 
92% versus HIV-: 85%), potentially a result of the greater burden of organism seen in 209 
HIV+ PCP. 43, 44 210 
BDG assays utilise a single positivity threshold for the detection of invasive fungal 211 
disease and it is not possible to confidently determine organism specific fungal 212 
aetiology based on the strength of positivity. However, for cases of PCP it is not unusual 213 
to see positivity greater than the upper limit of the assay (e.g. Fungitell >500pg/ml), 214 
even in the absence of IF staining of respiratory samples. 47, 48 In the study of Damiani et 215 
al. the median Fungitell BDG concentration across 17 cases of PCP was 1945pg/ml 216 
(range: 122-8000pg/ml), with 10 of the cases generating concentrations >500pg/ml, 217 
and 14 cases with concentrations >300pg/ml. 49 Both control and Pneumocystis 218 
colonised patients had BDG concentrations below 90pg/ml. Differentiation of 219 
colonisation from infection was also possible using the Beta-Glucan test Wako™ 220 
(colonisation: 49pg/ml versus infection: 173pg/ml).50 Compared to the Fungitell assay 221 
the overall BDG concentrations generated by the Wako assay were lower for all 222 
categories of infection, potentially reflecting the differences in reaction kinetics and 223 
subsequent positivity thresholds and highlighting the necessity to independently 224 
validate different kits. When testing serum by the Fungitell assay using a positivity 225 
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threshold of 300pg/ml the sensitivity, specificity, LR+ve and LR-ve were 91%, 92%, 226 
11.4 and 0.1, respectively indicating that the assay could be used to both confirm and 227 
exclude disease.30 228 
With Pneumocystis primarily infecting the respiratory tract a limitation of BDG is poor 229 
clinical  utility when testing respiratory samples. Candida species are common 230 
commensals of the mucosal membranes and airway colonisation by other fungi is 231 
possible the presence of elevated BDG concentrations are not indicative of disease, and 232 
could be misleading in symptomatic patients. In one study the specificity of BDG testing 233 
of BAL samples was only 68%, compared to 92% when testing serum and 234 
reproducibility was poor with only 5.9% of retested BAL samples confirming the earlier 235 
result. 48 Even when using higher positivity thresholds BDG specificity when testing BAL 236 
fluid remained compromised (241pg/ml: 39%; 783pg/ml 79%).30 While there has been 237 
a successful attempt to differentiate PCP infected from colonised/uninfected patients 238 
based on BDG concentration.  Others have found receiver operator characteristic curve 239 
analysis to be of limited use in defining BDG BAL threshold. 30. 48, 51 240 
 241 
Molecular Investigations 242 
The use of molecular based tests for the diagnosis of PCP continues to be described with 243 
too many studies to be discussed individually. 13 While the focus on development of 244 
local assays provides technological diversity, it prevents methodological 245 
standardisation, which remains limited, and can affect the outcomes of meta-analyses. 246 
Nevertheless, meta-analyses determining the performance of PCP PCR show excellent 247 
performance for  diagnosis (LR+ve: ηͳͲȌ, but more so the exclusion of PCP ȋNPV: η99%, 248 
LR-ve: ζͲ.Ͳ͵Ȍ ȋTable ͶȌ.52-54  249 
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Sub-group analysis using microscopy as the reference standard showed performance 250 
(Se: 97%, Sp: 93%) comparable to the combined population, whereas specificity was 251 
increased to 96% when using other reference standards.52  Comparison of performance 252 
in HIV+ and HIV- cohorts was similar. 54 When testing BAL the sensitivity and specificity 253 
were 100% and 87%, respectively, but when induced sputa were incorporated 254 
sensitivity was 97% and specificity was 93%. 54 Comparison of performance when PCR 255 
testing BAL fluid with oropharyngeal wash fluid (OW) showed OW to have significantly 256 
lower sensitivity (76%) but higher specificity (93%), indicating that the PCR detection 257 
of Pneumocystis in the upper airways is a good indicator PCP (LR+ve 10.4, compared to 258 
8.0 in BAL).54 While PCP PCR negativity when testing BAL fluid appears to provide the 259 
ability to confidently exclude PCP, false negatives associated with a mutation in the 260 
large sub-unit mitochondrial rRNA has been noted and as with all molecular based 261 
assay surveillance for genetic drift is required, but complicated by the lack of 262 
surveillance cultures. 55 The use of nasopharyngeal aspirates cannot be used to exclude 263 
PCP, but may provide a useful adjunct diagnostic test in combination with other 264 
markers (e.g. BDG). 56 265 
From a technical perspective, the use of commercial kits for cell wall disruption and 266 
nucleic acid extraction affected specificity, while targeting the ITS region for PCR 267 
amplification improved sensitivity, but, along with targeting the large sub-unit 268 
mitochondrial rRNA, decreased specificity. 54 The use of nested-PCR provided 269 
significantly lower specificity which could be attributed to its potential to detect sub-270 
clinical levels of Pneumocystis, although could also be an effect of the contamination 271 
prone process. 53 Nowadays the use of conventional PCR amplification systems has been 272 
superseded by real-time (quantitative) PCR platforms that are associated with 273 
improved specificity but also have been used to differentiate Pneumocystis infection 274 
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from colonisation. 54, 57-59 When interpreting the significance of the burden the 275 
underlying condition of the patient and quality of sample must be considered. For 276 
example, in one study using a real-time PCR cycle threshold (Ct) of 27 was associated 277 
with 100% specificity for the diagnosis of PCP in HIV+ patients, yet the optimal Ct in 278 
HIV- patients was 31 cycles and associated specificity was 80%. 57 Conversely, an upper 279 
Ct of 35 cycles generated a sensitivity of 80% and 1/5 PCP HIV- cases would be missed. 280 
When setting thresholds to confirm or exclude disease it is critical that specificity and 281 sensitivity are η9ͷ%, respectively. Otherwise the utility of the assay is compromised 282 
and results of limited clinical value. 283 
When interpreting low level PCP PCR positives (Ct >35) it is important to determine 284 
both the quality of sampling and also understand the presentation of clinical disease in 285 
HIV-patients with a low fungal burden but significant immune response. Theoretically, 286 
human DNA can be used as a surrogate for sample assessment. Low levels of human 287 
DNA could represent poor sample quality, whereas if a large quantity is present it could 288 
represent a strong immune response. For reference it is essential to know the typical 289 
burden of human DNA in respiratory samples and it is also requires that sampling is 290 
standardised, which for BAL remains highly variable. The sampling of the upper 291 
respiratory tract is less variable and has been associated with greater specificity. 54 292 
Given the broad range of available PCP PCR assays it may be wise for centres to 293 
incorporate commercially manufactured and standardised tests that have developed an 294 
understanding of how to interpret, in particular low level positives. In a comparative 295 
study of three commercial assays (Pneumocystis jirovecii (carinii) – FRT PCR Kit 296 
(AmpliSens), MycAssay Pneumocystis (Myconostica) and  real-time PCR Pneumocystis 297 
jirovecii (Bio-Evolution)) the sensitivity and specificity when testing proven/probable 298 
PCP was 100%, 100%, 95% and 83%, 93% and 100%, respectively, and sample 299 
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concordance between the Amplisens and MycAssay were excellent (Kappa: 0.85). 60 One 300 
interesting concept is the development of a commercial real-time PCR for both the 301 
detection of organism and dihydropteroate synthase (DHPS) point mutations associated 302 
with resistance to sulfa-based drugs such as sulfamethoxazole and dapsone, used for 303 
both prophylaxis and treatment of PCP. 61 Using a positivity threshold of 32 cycles the 304 
sensitivity and specificity of the PneumoGenius® assay were 70% and 82%, 305 
respectively. Performance may have been affected by the classification of disease based 306 
on clinical findings in high risk hosts responding to PCP therapy but missing a 307 
mycological criterion. Nevertheless, the assay was able to screen for sulfa-resistance 308 
direct from 89 samples and showed a 4.5% resistance rate. 61 309 
With more than 60 types of P. Jirovecii identified and approximately 30% of PCP cases 310 
infected with multiple types, the ability to investigate transmission and clusters has 311 
been hampered by the difficulty in cultivating Pneumocystis. 62, 63 Molecular based 312 
methods can also be used to determine the epidemiology and transmission of infection 313 
and to investigate potential outbreak scenarios and multi-locus sequence typing and 314 
multi-locus real-time mutation frequencies have been used. 10, 64, 65 315 
 316 
Combination testing 317 
While the reference standard for the diagnosis of PCP remains microscopic evidence, 318 
usually IF, within a respiratory specimen its limited sensitivity cannot be used to 319 
exclude disease. 12, 13, 17 The question remains whether by combining more sensitive 320 
tests specificity of diagnosis can be improved while maintaining confidence in exclusion. 321 
In the adult haematology population, current guidelines suggest a diagnostic algorithm 322 
involving real-time PCR and IF testing of BAL in patients with a clinical suspicion of 323 
disease. If both are positive, a diagnosis of PCR is confirmed and vice versa. 13 If PCR is 324 
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positive, but IF negative, diagnosis is made if high burdens are detected, For low 325 
burdens, additional BDG testing is recommended. If PCR is negative but IF positive then 326 
this is considered technically inconsistent and the quality of either result is questioned. 327 
13   This begs the questioned why IF is still being performed, rather than being replaced 328 
with PCR in combination with BDG testing. In a study comparing circulating biomarkers 329 
with PCP lung burden 96% of (25/26) patients that were BAL PCP PCR positive but IF 330 
negative were also positive by BDG, as were all (10/10) patients that were BAL PCP PCR 331 
and IF positive. 66 Conversely, 29% (10/34) of PCP PCR and IF negative were BDG 332 
positive, although 15/34 were diagnosed with proven/probable invasive aspergillosis. 333 
Given the panfungal nature of BDG, it makes sense to perform a primary investigation 334 
using PCP PCR, and if positive confirm, dependent on pulmonary burden, with BDG 335 
testing. 49 When BAL samples are not available BDG testing of serum is recommended 336 
where negativity can be used to exclude PCP, but positivity should be confirmed by PCR 337 
(or IF) testing of less invasive respiratory samples. 13 338 
The combination of BDG testing in association with LDH levels permits a fully non-339 
invasive sampling regime and has been successfully evaluated for the diagnosis of PCP. 340 
When using optimal thresholds (BDG: 400pg/ml; LDH: 350U/l) specificity was 84%. 67 341 
A further serological biomarker multi-centre study evaluated BDG, LDH, Krebs von den 342 
Lungen-6 antigen (KL-6, a potential marker of interstitial pneumonitis) and S-adenosyl 343 
methionine (SAM, a metabolic intermediate possibly exogenously required by 344 
Pneumocystis) to aid in the diagnosis of PCP. 68 The best overall performance was by 345 
combining BDG with KL-6 (Se: 94% Sp: 90%). Although sensitivity was slightly higher 346 
when combining BDG with LDH, specificity was compromised (Sensitivity: 97% 347 
Specificity: 72%). For all these approaches it could be argued that the absence of 348 
organism specific assay compromises confidence in diagnosis, and incorporating a 349 
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Pneumocystis specific PCR is required. If this is the case then the combination of 350 
PCR/BDG is preferable to using another non-specific serological biomarker. 351 
 352 
MANAGEMENT 353 
PCP can run a fulminant course, particularly in HIV negative individuals and early 354 
treatment improves prognosis.  Disease can be stratified according to mild, moderate or 355 
severe depending on presenting symptoms, oxygen saturation and chest radiographic 356 
changes. Requirement for mechanical ventilation and vasopressors is a poor prognostic 357 
feature. 358 
Clinicians should commence antimicrobials on the basis of clinical suspicion and before 359 
diagnostic investigations have been performed. Increasingly, sensitive molecular and 360 
biomarker detection is picking up patients who have only minimal symptoms or who 361 
are asymptomatic and this can present some diagnostic dilemma. Prophylaxis of at risk 362 
patients is also considered a mainstay of management.  Guidelines for the prophylaxis 363 
and treatment have been developed for different groups and are summarized in Table 5.  364 
Although included within the fungal kingdom on the basis of cell wall composition and 365 
structure combined with nucleotide sequence similarity, Pneumocystis jirovecii is not 366 
susceptible to polyene and azole antifungal drugs, due to the absence of ergosterol from 367 
its cell wall.  The different morphological forms also show varying susceptibility to 368 
other drugs with in vitro inhibition of ascospores (cyst) but not trophic forms by 369 
echinocandins.  Trimethoprim, sulfa drugs and pentamidine form the main stays of 370 
treatment. Corticosteroids are of proven benefit in HIV positive individuals with disease 371 
but a beneficial role has not been established for other patient groups. The most 372 
effective way of preventing PCP in people living with HIV is by immune-reconstitution 373 
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through the administration of effective anti-retroviral therapy. Prophylaxis should be 374 
administered until immune reconstitution has been achieved. 375 
 376 
Prophylaxis 377 
Recommendations for prophylaxis are comprehensively reviewed in the ECIL guideline 378 
although this focuses on patients with haematological malignancies and undergoing 379 
SCT.16 380 
Prophylaxis is recommended in risk groups that include HIV positive patients with CD4 381 
counts less than 200 cells/mm3, transplant patients, and patients with high-risk 382 
haematological malignancies as well as a growing number of patients receiving disease 383 
modifying drugs and aggressive chemotherapeutic regimens for an array of 384 
inflammatory and malignant diseases. 69 This last group is increasing rapidly and 385 
includes patients receiving TNF blockade (infliximab, adalimumab, etanercept), anti- 386 
IL1 therapies (alemtuzamab). B-cell blockade (Rituximab) and selective T cell blockade 387 
in addition to anti-purine drugs, bendamustine, nucleoside analogues and high-dose 388 
steroids for prolonged periods. 70  389 
Cotrimoxazole remains the drug of choice for both prophylaxis and treatment.  390 
Systematic review and meta-analysis have shown significant benefit in preventing PCP 391 
and reducing PCP related mortality although the trials analysed focused on 392 
haematological malignancy and solid organ transplant patients and tended to be small 393 
and of poor quality. 71 The benefit in HIV populations is well documented and the effect 394 
on survival is compelling but there are few data in other groups of patients particularly 395 
those receiving disease modifying drugs. Prophylaxis is still not universally used in 396 
haematological patients receiving rituximab despite recommendations for prophylaxis 397 
in rheumatoid arthritis. 69  398 
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A variety of different prophylactic regimens of cotrimaxazole have been used, Daily, 399 
alternative day, and thrice weekly have all been used and the optimum regimen in 400 
different patient groups has not been determined. ECIL guidelines recommend either 401 
one single strength tablet (480mg) daily or one double strength (960mg) table three 402 
times a week. 16 403 
Intolerance of cotrimaxazole and adverse events (including, rashes and marrow 404 
suppression) are relatively frequent and may necessitate use of second-line agents. 405 
Inhaled pentamidine, dapsone and atovaquone have all be used effectively but are 406 
considered inferior to cotrimaxazole on the basis of largely retrospective comparisons 407 
and should only be used after careful consideration.   408 
It may be possible to reintroduce cotrimaxazole when adverse events resolve.  409 
Inhaled pentamidine has the advantage that it is administered monthly but requires a 410 
jet nebulizer and side-room facilities for effective and safe administration. Dapsone can 411 
trigger methaemoglobinaemia in susceptible individuals and patients should be 412 
screened for glucose-6- phosphate dehydrogenase deficiency before use. Other serious 413 
side-effects include a potentially fatal idiosyncratic dapsone-hypersensitivity syndrome 414 
causing fever, skin rash, eosinophilia, and major organ dysfunction. Atovaquone is 415 
generally better tolerated and probably as effective as the other second line agents. Use 416 




Recommendations are comprehensively reviewed in the ECIL guideline although this 419 
focuses on patients without HIV disease.15 420 
 High dose cotrimoxazole is the treatment of choice given intravenously at 421 
20mg/kg/day in 2-4 divided doses. For severe disease, primaquine plus clindamycin is 422 
used for intolerant and refractory cases. Intravenous pentamidine has also been used 423 
but experience is confined to case reports. For mile to moderate disease, atovaquone 424 
may be used second-line. The use of echinocandins is not recommended. 425 
Adjunctive corticosteroids (50-80mg daily) have established benefit in severe disease in 426 
patients with HIV but use in other patients should be considered on a case to case basis. 427 
Treatment durations of 14-21 days are recommended depending on response and 428 
severity of disease.  Patients can be slow to respond and may actually deteriorate 429 
clinically in the first few days of treatment.  Assessment of failure to respond cannot be 430 
made confidently during the first week of treatment. 431 
 432 
CONCLUSIONS 433 
With the incidence of PcP increasing through infection in high-risk non-HIV-infected 434 
patients, it is essential that ever effort is made to optimize the diagnosis of PcP. While the 435 
development of culture-based methods is a breakthrough in the field, they come at a time 436 
when reliance on culture to attain a microbiological diagnosis is less and the role of PcP 437 
culture more suited to the academic scenario. Non-mycological laboratory markers and 438 
clinical presentation although satisfactory to initiate therapy in high-risk individuals do not 439 
provide a definitive diagnosis. Diagnosis by IF remains the reference standard, but the 440 
development of non-culturebased strategies has aided the diagnosis of other fungal 441 
diseases (e.g. invasive aspergillosis) and the combination of PcP 442 
PCR along with BDG testing may be suitable alternative, especially given the low incidence 443 
of disease. With both prophylaxis and treatment based on the primary use of 444 
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cotrimoxazole, the emergence of resistance to sulfa-based drugs is of concern, and in the 445 
absence of culture, molecular techniques are the only route available to identifying 446 
resistance in Pneumocystis. 447 
Expert commentary 448 
A weakness in the diagnosis of PcP remains the resistance to move away from microscopic 449 
based diagnosis. It is accepted that sensitivity is far from optimal and false negatives will 450 
occur, but this conflicts with the low incidence of disease that dictates testing be used to 451 
exclude disease, with subsequent sensitivity paramount. For a disease where recent 452 
incidences across HIV, hematology and solid organ transplantation were approximately 1% 453 
or less, the pretest probability of not having PcP is approximately 99% and it is 454 
far easier to use a highly sensitive (≥95%) test to confidently exclude disease than a highly 455 
specific (≥95%) assay to confirm it [19–21]. For example, for a disease with a prevalence of 456 
1% and an assay with a good sensitivity and specificity of 90% the posttest probability of 457 
disease associated with a positive result is 8.3%, whereas the posttest probability of no 458 
disease associated with a negative result is 99.9%. Increasing specificity to 95% and 99%, 459 
respectively, increases the posttest probability of disease, when the assay is positive to 460 
15.4% and 47.6%, respectively. So even with an excellent specificity of 99% it is 461 
more likely that the patient does not have disease. If this applied specifically to PcP and 462 
typical performance of PCR and IF microscopy then it is clear that even though IF provides 463 
a greater degree of diagnostic confidence it is still not infallible, and its lower sensitivity 464 
limits its application to exclude disease. For PCR to take over as the reference method for 465 
PcP diagnosis standardization is required and commercially produced kits, international 466 
collaborative efforts of the Fungal PCR initiative and external quality control exercises 467 
(Quality Control for Molecular diagnosis (QCMD)) will assist this process. With a reliance on 468 
testing lower respiratory tract specimens (e.g. BAL), the testing for PcP will always be 469 
balanced against the risk of obtaining the sample (e.g. during thrombocytopenia). 470 
Consequently, clinical diagnosis, based on risk factors, symptoms and response to therapy, 471 
will occur, but in cases not responding to therapy, this could reflect a pneumonia caused by 472 
a different etiology or possibly a case of treatment- resistant PcP. Moving away from 473 
testing BAL specimens to less-invasive specimens, such as upper respiratory samples or 474 
even blood, alleviates the clinical pressure and also removes the need to standardize 475 
bronchoscopy, which varies considerably between centers and impacts on test 476 
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performance and interpretation. It is unlikely that a single noninvasive test will be able to 477 
provide both a diagnosis and the ability to exclude disease, but combining PCR of upper 478 
respiratory tract specimens with BDG testing of serum may do so. Currently, large scale 479 
performance data is limited but the ability to offer this noninvasive approach will surely 480 
appeal to clinicians and it is hoped there will be sufficient evidence in the near future to 481 
confirm the applicability of this strategy. 482 
Five-year view 483 
Within the next five years, diagnosis of PcP will become less reliant on IF, with the potential 484 
for IF to become obsolete. The standardization of PCR through the efforts of the Fungal PCR 485 
initiative and through commercial development coupled with increasing prospective 486 
information on the performance of real-time PCR will provide greater understanding of 487 
interpretation of low-level PCR positives, across a range of patient populations. Combining 488 
PCR with BDG will further reduce the requirement for IF diagnosis. The development of 489 
syndromic testing using multiplex molecular methods may allow PcP to be detected 490 
alongside a range of other respiratory pathogens (e.g. Abbott IRIDICA) in a single assay. 491 
Whether BDG could be combined with Pneumocystis-specific immunology (antibodies or 492 
antigen) and provide a totally serological approach is yet to be proved. Although antibody 493 
ELISA tests targeting the major surface glycoproteins (Msg A, Msg B and Msg C) in 494 
Pneumocystis have shown promise, there is very little in the way of standardization and 495 
commercialization [84]. 496 
There is also the problem of positivity in healthy individuals who have been exposed to 497 
Pneumocystis, and as antibody levels peak almost a month post recovery, whether 498 
significant antibody positivity will occur too late to be clinically useful 499 
[84–86]. 500 
The application of next-generation sequencing (NGS) in relation to Pneumocystis is limited 501 
by the lack of culture. The ability to perform cell culture may alleviate the problem and 502 
should be focused on strains of Pneumocystis which are resistant to treatment to identify 503 
new molecular mechanisms of resistance. NGS may also provide further insights into 504 
transmission and sources of infection, allowing improved infection control measures to be 505 
applied. By combining direct PCR testing of nucleic acid extracted from respiratory 506 
specimens, NGS can provide enhanced broad-range diagnosis in symptomatic 507 
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patients, but also an understanding of the respiratory microbiome and the prevalence of 508 
Pneumocystis colonization in asymptomatic individuals. 509 
From a clinical perspective, it is likely that the population at risk of PcP will expand with 510 
cases diagnosed in novel cohorts and the application of resistance monitoring is likely to 511 
become a standard procedure and has already been trialled in Europe where anthropophilic 512 
transmission and suboptimal prophylaxis were identified as risk factors [87]. 513 
Key issues 514 
The population of patients at risk from PCP is growing and changing. While the 515 
 incidence of disease in the HIV cohort may be reducing due to successful anti-516 
 retroviral therapy the incidence in other populations (Haematology, particularly 517 
 conditions affecting lymphocyte count and function; solid organ transplant 518 
 recipients, including renal transplants; solid malignancy; rheumatoid conditions; 519 
 pre-existing chronic lung conditions; patients with connective tissue disorders 520 
 and those receiving immuno-modulatory therapies) is increasing. 521 
 In high risk patients clinical presentation and radiology is sufficient for initiating 522 
empirical therapy but should not be used as definitive diagnosis, and on 523 
commencing therapy every effort should be made to achieve an organism 524 
specific mycological diagnosis. 525 
 The reference method for the diagnosis of PCP is the microscopic examination of 526 
respiratory samples, preferably BAL fluid, with immuno-fluorescent staining 527 
using anti-Pneumocystis antibodies targeting both ascus and trophic forms.  528 
 Negative microscopy cannot be used to exclude PCP, but given the incidence of 529 
disease exclusion of disease is a sensible use of mycological testing. Both PCP 530 




 BDG testing of serum and plasma is very sensitive (>90%) but not sufficiently 533 
specific and given the broad detection range coupled with the susceptibility of 534 
the at-risk patient population it should be combined with an organism specific 535 
test. The BDG testing of respiratory samples is not recommended and adds very 536 
little to testing serum/plasma. 537 
 Standardisation of PCP PCR methodology would be beneficial although meta-538 analyses of current methodology provide high ȋη9Ͳ%Ȍ sensitivity and specificity 539 
when testing BAL fluid. PCP PCR sensitivity is reduced when testing upper 540 
respiratory samples, although specificity is increased. Commercial PCP PCR tests 541 
will assist in methodological standardisation and have the ability to identify 542 
genetic markers associated with resistance to sulfa-based therapy direct from 543 
the specimen. Molecular based methods can be used to identify origin of 544 
infection, transmission routes, outbreaks situations as well as epidemiology and 545 
evolution of the organism.  546 
 Combination testing, involving IF microscopy and PCR on BAL, or in the absence 547 
of BAL, BDG on serum/plasma and PCR/IF on an upper respiratory sample is 548 
recommended. Albeit there is a strong argument for combining PCR and BDG 549 
alone. 550 
 Guidelines for the prophylaxis and treatment of PCP in HIV, solid organ 551 
transplantation, haematology and rheumatoid conditions are available.  552 
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Table 1. A summary of risk factors for Pneumocystis pneumonia. 826 
Underlying condition Risk Factor 
HIV/AIDSa CD4 count <200cells/µl, 
CD4 cell percentage <14%, 
Previous PCP, 
Oral Candidiasis, 
Higher HIV burden, 
Ongoing bacterial pneumonia. 
Haematological malignancyb CD4 count <200cells/µl, 
Lymphocytopenia, 
Immuno-suppression to prevent rejection 
of allogeneic haematopoietic SCT.  
For autologous SCT patients receiving 
purine analogues or high dose 
corticosteroids. 
GVHD, 
ALL patients or those with 
lymphoproliferative disorders (CML, NHL, 
and multiple myeloma) as a result of 
chemotherapy including 
R-CHOP14, FCR, AVBD, gemcitabine or 
high-dose methotrexate. 
Monoclonal antibodies (e.g. rituximab). 
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Exposure to cases of PCP. 
Inflammatory Disease Administration of multiple ȋη͵Ȍ 
immunomodulatory medications, 
including: Calcineurin inhibitors and/or 
anti-TNF therapy. 
Corticosteroids. 
a Information collated from CDC, NIH, HIVMA/IDSA guidelines (11) 827 
b Information collated from ECIL guidelines (16) 828 
c Information collated from American Society of Transplantation guidelines (17) 829 
  830 
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Table 2. Studies comparing the performance of various microscopic staining and 831 
fluorescent kits for the detection of PCP. When interpreting results the influence of 832 
incorporation bias on performance parameters should be considered, as in many 833 
studies the results, particularly in combination with the other tests have been used to 834 
define cases and controls. 835 
Reference Assay Performance Parameter 
Sensitivity Specificity PPV NPV LR+ve LR-ve DOR 
37 CW 73.8% 99.6% 98.0% 93.4% 184.5 0.26 709.6 
MF 90.8% 94.7% 81.9% 97.5% 17.1 0.097 176.3 
DQ 48.4% 99.6% 96.9% 88.0% 121.0 0.51 237.3 
GMS 76.9% 99.2% 96.2% 94.2% 96.2 0.23 418.3 
38 CB 74.3% 99.6% 92.9% 98.0% 165.6 0.3 552.0 
MoF 60.0% 99.3% 87.5% 96.9% 89.2 0.4 223.0 
Giemsa 34.6% 100% 100% 95.1% >346a 0.7 >494.3a 
39 GMS 50% 100% 100% 96.5% >500a 0.5 >1000a 
Giemsa 50% 100% 100% 96.5% >500a 0.5 >1000a 
40b MoF 93.1% 100% 100% 95.5% >931a 0.07 >13300a 
DQ 87.9% 97.6% 98.1% 85.4% 36.6 0.12 305.0 
GMS 89.7% 95.2% 96.3% 87.0% 18.7 0.11 170.0 
PCIF 94.8% 88.1% 91.7% 92.5% 8.0 0.06 133.3 
a Values have been generated using a specificity of 99.9% to overcome ∞ 836 
b Results represent combined induced sputum and bronchoalveolar lavage fluid testing 837 
Key:  CW:  Calcofluor white  GMS:  Grocott-Gomori methenamine silver 838 
MF:  Merifluor Pneumocystis CB: Calcofluor blue  839 
DQ:  Diff-Quik   MoF:  Monofluo™ Pneumocystis jirovecii 840 
PCIF: P. carinii IF kit  841 
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Table 3. The performance of (1-3)-β-D-Glucan Testing for the diagnosis of Pneumocystis 842 
pneumonia as determined by meta-analyses. The table contains data determined for 843 
range of susceptible patients testing with various BDG assays. 844 
 845 
Parameter Study 
Karageorgopoulos (40) Onishi (41) Li (42) 
Cases/Total (n/N) 357/2080 286/2331 433/2195 
Sensitivity (%) 94.8 95.5 90.8 
Specificity (%) 86.3 84.3 78.1 
PPV (%) 54.3 46.0 50.5 
NPV (%) 99.0 99.3 97.2 
LR +ve 6.9 6.1 4.1 
LR -ve 0.06 0.05 0.12 
DOR 115 122 34.2 
 846 
Key:  847 
PPV:   Positive predictive value 848 
NPV:   Negative predictive value 849 
LR +ve:  Positive likelihood ratio 850 
LR -ve:  Negative likelihood ratio 851 
DOR:   Diagnostics Odds ratio852 
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Table 4 The performance of PCR for the diagnosis of Pneumocystis pneumonia as 853 
determined by meta-analyses. The table provides the performance for PCP PCR when 854 
testing both HIV+ and HIV- patients, when testing upper and lower respiratory tract 855 
specimens, and is irrespective of differing technical details. 856 
 857 
Parameter Study 
Summah (50)a Fan (51) Lu (52) 
Cases/Total (n/N) 506/2330 606/1793 416/2505 
Sensitivity (%) 97 98 99 
Specificity (%) 94 91 90 
PPV (%) 82 85 66 
NPV (%) 99 99 >99 
LR +ve 16.2 10.9 9.9 
LR -ve 0.03 0.02 0.01 
DOR 540 545 990 
 858 
a Due to incomplete information the case and total population were calculated using 859 
sample numbers. 860 
 861 
Key:  862 
PPV:   Positive predictive value 863 
NPV:   Negative predictive value 864 
LR +ve:  Positive likelihood ratio 865 
LR -ve:  Negative likelihood ratio 866 
DOR:   Diagnostics Odds ratio867 
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Table 5. Therapeutic Recommendations for the management of Pneumocystis pneumonia in adults 
Recommendation Guidelines (population) 











Population 1) CD4 count <200cells/µl 
2) CD4 cell <14% 
3) CD4 count 200-250 cells/µl in 
the absence of regular 3 
month CD4 monitoring 
4) Not patients receiving 
pyrimethamine/sulfadiazine 
for toxoplasmosis 
1) ALL  





Optional: Lymphoma with R-
CHOP14 or escalated BEACOPP, 
nucleoside analogues, 
radiotherapy for brain 
tumours/metastasis with 
steroids 
1) All SOT, especially lung 
transplant 
2) Increasing immuno-
suppression to prevent graft 
rejection 
3) Recurrent or chronic CMV 
infection 
4) Prolonged course of corticosteroids ȋ>ʹͲmg for η 
2weeks) 
5) Prolonged neutropenia 
6) Episodes of autoimmune 
disease 
Duration Until CDͶ count ηʹͲͲ cells/µl for > ͵ 
months 
1) Induction to end of maintenance 
2) Engraftment for at least 6 months 
until immuno-competent 
A minimum 6-12 months post-
transplant for all SOT recipients. 
Patients with lung or small bowel 
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3) More than 6 months post 
completion 
4) Minimum of 6 months post 
completion 
grafts or those prior PCP or chronic 
CMV disease may require lifelong 
prophylaxis 
Therapy a Front line: 
Trimethoprim/sulfamethoxazole one 
single-strength (80mg TMP/400mg 
SMX) daily or one double strength 





double strength tablet (160mg 
TMP/800mg SMX) three times per 
week 
Dapsone (50mg twice daily) 
Dapsone (200mg) + pyrimethamine 
(75mg) + leucovorin (25mg) weekly 
Dapsone (50mg daily) + 
Front line: 
Trimethoprim/sulfamethoxazole one 
single-strength (80mg TMP/400mg 
SMX)/day or double strength tablet 




Dapsone (50mg twice daily) 




single-strength (80mg TMP/400mg 
SMX)/day or double strength tablet 
(160mg TMP/800mg SMX)/day or 
three per week. 
 
Second line: 
Dapsone (50-100mg once a day) 
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pyrimethamine (50mg weekly) + 
leucovorin (25mg weekly)  
Pentamidine aerosols (300mg per 
month) 














Population HIV/AIDS patients with 
suspected/diagnosed PCP 
Haematological malignancy, solid 
cancer, solid organ transplant, 
autoimmune/inflammatory conditions 
with suspected/diagnosed PCP 
All SOT with suspected/diagnosed 
PCP 
Duration 3 weeks A minimum of 14 days At least 14 days, extended to 21 days 
for severe cases 
Therapy a Frontline: 
Trimethoprim/sulfamethoxazole (15-
20mg/kg TMP; 75-100mg/kg SMX 
per day) 
For moderate to severe disease (i.e. 
hypoxemia) adjunctive 












(15-20mg/kg TMP; 75-100mg/kg 
SMX per day) with TMP administered 
by IV every 6-8h. For hypoxemic 
patients potentially in combination 




Second line for severe disease: 
Primaquine and clindamycin 
(30mg/(600mgx3)) per day 
Pentamidine IV (4mg/kg/day) 
 
Second line for mild/moderate 
disease: 
 Dapsone (100mg daily) + 
trimethoprim (15mg daily) 
Atovaquone (750mg BID) 
Second line: 
Primaquine and clindamycin 
(30mg/(600mgx3)) per day 
Pentamidine IV (4mg/kg/day) 
Second line:  
IV Pentamidine (Initially 4mg/kg/day 
over 1-2h) Recipients of 
pancreas/islet transplants should 
receive an alternative second line 
therapy. 
a Where possible only the recommendation receiving an ǲAǳ grading or the preferred drug of choice have been listed. 
